Tagged with Russia

Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…

Ukraine Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the lead of businesses in other industries in severing ties with Russia, citing the importance of continuing to supply essential medicines…

Russia The top 10 Russian pharma companies ranked by revenues for 2020. R-Pharm leads the way, followed by BIOCAD and Pharmstandart-Leksredstva. Made with Visme Infographic Maker

Russia The latest news from Russian healthcare and life sciences, including the WHO’s decision to suspend the approval process for the country’s Sputnik V COVID vaccine, hesitant uptake of Sputnik V both at home and abroad, and an in-depth feature on Russia’s untreated pain epidemic.     Sputnik V: WHO suspends…

Europe Drawing from the 2021 edition of the EFPIA’s comprehensive annual data review of the European pharma industry, we present the Top 5 countries across a variety of pharma metrics: from market size to R&D spend, production, exports, imports, and generics penetration.   Made with Visme Infographic Maker   Made with…

Russia Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable tool in the global fight against COVID-19. Sputnik V is now approved in a number of countries, but questions are…

Russia The latest Russia Pharma News, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce insulin in Venezuela, the bypassing of Gilead’s Remdesivir IP, and the Russian government’s decision to delay approvals of Chinese vaccines in favor of local shots.   Russian Biocad plans to produce…

Russia The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025, limits on pharma companies’ ability to patent other forms of already known chemical compounds in Russia, and the Sputnik COVID-19 vaccine’s geopolitical cachet.   Russia to allocate $7.4 bln for healthcare…

Russia Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet been completed, critics both from within Russia and internationally have raised concerns as to the vaccine’s safety and efficacy.  …

Russia Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association and new breakthroughs in Coronavirus diagnostics.   Government amends legislation around emergency response to diseases The State Duma, as is…

Russia The year 2019, which continued the trend of rapid and numerous changes in healthcare regulations in Russia, was rich with expectations, events and legislative proposals aiming to reform the Russian pharmaceutical industry: medical drugs labeling, reform of price determination, new procedure of entry into drugs civil circulation, amendments to regulatory…

Russia The top 10 pharmaceutical companies in the Russian hospital market for the nine months up to November 2019, sorted by percentage share of total hospital purchases. Domestic player Biocad leads the way, followed by global firms MSD and Pfizer.   Made with Visme Infographic Maker     The top 10…